Item 9 Labs Corp
OTC:INLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Item 9 Labs Corp
OTC:INLB
|
US |
|
A
|
Alltronics Holdings Ltd
HKEX:833
|
HK |
|
Direct Marketing MiX Inc
TSE:7354
|
JP |
|
AT & S Austria Technologie & Systemtechnik AG
F:AUS
|
AT |
|
Calliditas Therapeutics AB
STO:CALTX
|
SE |
|
Spire Healthcare Group PLC
LSE:SPI
|
UK |
|
Pangaea Oncology SA
MAD:PANG
|
ES |
|
A
|
American International Ventures Inc
OTC:AIVN
|
US |
|
K
|
KH Electron Co Ltd
KOSDAQ:111870
|
KR |
|
Metro Performance Glass Ltd
NZX:MPG
|
NZ |
|
N
|
Nido Education Ltd
ASX:NDO
|
AU |
Profitability Summary
Item 9 Labs Corp's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Profitability Score
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Profitability Score
Margins
Earnings Waterfall
Item 9 Labs Corp
Margins Comparison
Item 9 Labs Corp Competitors
| Country | Company | Market Cap |
Gross Margin |
Operating Margin |
Net Margin |
||
|---|---|---|---|---|---|---|---|
| US |
|
Item 9 Labs Corp
OTC:INLB
|
701.8 USD |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD |
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP |
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD |
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF |
Loading...
|
Loading...
|
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
Loading...
|
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD |
Loading...
|
Loading...
|
Loading...
|
Return on Capital
Return on Capital Comparison
Item 9 Labs Corp Competitors
| Country | Company | Market Cap | ROE | ROA | ROCE | ROIC | ||
|---|---|---|---|---|---|---|---|---|
| US |
|
Item 9 Labs Corp
OTC:INLB
|
701.8 USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
